Atara Biotherapeutics(CH:ATRA)
CH:ATRA
Atara Biotherapeutics financials statements
Atara Biotherapeutics (ATRA) Ratios
0 Followers
Atara Biotherapeutics Ratios
CH:ATRA's free cash flow for Q3 2026 was $-879.00K. For the 2026 fiscal year, CH:ATRA's free cash flow was increased by $0.00 and operating cash flow was $-879.00K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.82 | 0.48 | 0.72 | 3.74 | 3.64 |
| Quick Ratio | 0.82 | 0.40 | 0.65 | 3.72 | 3.64 |
| Cash Ratio | 0.57 | 0.19 | 0.18 | 1.18 | 1.00 |
| Solvency Ratio | 0.59 | -0.39 | -1.02 | -0.89 | -1.75 |
| Operating Cash Flow Ratio | -3.41 | -0.51 | -1.36 | -3.43 | -2.08 |
| Short-Term Operating Cash Flow Coverage | -4.73 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -46.52M | $ -141.49M | $ -162.87M | $ 45.30M | $ 196.11M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 2.61 | 0.40 | 0.35 | 0.19 | 0.06 |
| Debt-to-Equity Ratio | -1.37 | -0.45 | -0.58 | 0.57 | 0.10 |
| Debt-to-Capital Ratio | 3.69 | -0.82 | -1.40 | 0.36 | 0.09 |
| Long-Term Debt-to-Capital Ratio | -5.61 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.53 | -1.12 | -1.67 | 2.97 | 1.67 |
| Debt Service Coverage Ratio | 2.65 | -16.41 | -50.33 | -595.91 | 0.00 |
| Interest Coverage Ratio | 9.46 | -18.08 | -52.22 | -752.05 | 0.00 |
| Debt to Market Cap | 0.19 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 4.51 | 6.47 | 14.91 | 17.67 | 7.55 |
| Net Debt to EBITDA | 1.15 | -0.25 | -0.12 | 0.10 | 0.24 |
| Profitability Margins | |||||
| Gross Profit Margin | 82.44% | 83.71% | -3.65% | 100.00% | -1286.44% |
| EBIT Margin | 30.23% | -62.66% | -3159.06% | -358.51% | -1673.85% |
| EBITDA Margin | 31.98% | -58.75% | -3102.73% | -349.62% | -1627.91% |
| Operating Profit Margin | 29.69% | -64.71% | -3219.48% | -441.25% | -1673.85% |
| Pretax Profit Margin | 27.09% | -66.24% | -3220.70% | -359.10% | -1672.05% |
| Net Profit Margin | 27.07% | -66.23% | -3220.88% | -359.12% | -1672.28% |
| Continuous Operations Profit Margin | 27.07% | -66.23% | -3220.88% | -359.12% | -1672.28% |
| Net Income Per EBT | 99.91% | 99.99% | 100.01% | 100.01% | 100.01% |
| EBT Per EBIT | 91.24% | 102.37% | 100.04% | 81.38% | 99.89% |
| Return on Assets (ROA) | 161.54% | -78.28% | -166.84% | -60.65% | -72.66% |
| Return on Equity (ROE) | -84.90% | 87.79% | 278.27% | -180.28% | -121.65% |
| Return on Capital Employed (ROCE) | 674.99% | 327.52% | -1185.69% | -94.29% | -93.96% |
| Return on Invested Capital (ROIC) | 222.66% | 721.74% | -778.42% | -90.16% | -93.25% |
| Return on Tangible Assets | 161.54% | -78.28% | -166.84% | -60.65% | -72.66% |
| Earnings Yield | 14.41% | -85.69% | -508.41% | -68.25% | -23.04% |
| Efficiency Ratios | |||||
| Receivables Turnover | 96.39 | 87.00 | 0.25 | 1.58 | 20.63 |
| Payables Turnover | 167.02 | 4.81 | 2.41 | 0.00 | 16.24 |
| Inventory Turnover | 0.00 | 1.97 | 0.92 | 0.00 | 0.00 |
| Fixed Asset Turnover | 16.92 | 3.14 | 0.15 | 0.86 | 0.25 |
| Asset Turnover | 5.97 | 1.18 | 0.05 | 0.17 | 0.04 |
| Working Capital Turnover Ratio | -3.34 | -2.34 | 0.10 | 0.26 | 0.06 |
| Cash Conversion Cycle | 1.60 | 113.44 | 1699.52 | 230.93 | -4.79 |
| Days of Sales Outstanding | 3.79 | 4.20 | 1452.17 | 230.93 | 17.69 |
| Days of Inventory Outstanding | 0.00 | 185.11 | 398.68 | 0.00 | 0.00 |
| Days of Payables Outstanding | 2.19 | 75.87 | 151.32 | 0.00 | 22.48 |
| Operating Cycle | 3.79 | 189.31 | 1850.85 | 230.93 | 17.69 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -4.06 | -9.18 | -45.55 | -66.29 | -58.86 |
| Free Cash Flow Per Share | -4.06 | -9.21 | -45.84 | -67.32 | -61.68 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -279.34 | -157.79 | -64.50 | -20.84 |
| Capital Expenditure Coverage Ratio | 0.00 | -279.34 | -157.79 | -64.50 | -20.84 |
| Operating Cash Flow Coverage Ratio | -0.96 | -1.57 | -3.33 | -3.77 | -7.80 |
| Operating Cash Flow to Sales Ratio | -0.42 | -0.53 | -22.51 | -4.25 | -10.84 |
| Free Cash Flow Yield | -22.45% | -69.19% | -357.57% | -82.09% | -15.65% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 6.93 | -1.17 | -0.20 | -1.47 | -4.34 |
| Price-to-Sales (P/S) Ratio | 1.88 | 0.77 | 6.34 | 5.26 | 72.58 |
| Price-to-Book (P/B) Ratio | -5.89 | -1.02 | -0.55 | 2.64 | 5.28 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -4.45 | -1.45 | -0.28 | -1.22 | -6.39 |
| Price-to-Operating Cash Flow Ratio | -4.45 | -1.45 | -0.28 | -1.24 | -6.69 |
| Price-to-Earnings Growth (PEG) Ratio | -0.06 | 0.01 | -0.01 | 0.04 | 0.35 |
| Enterprise Value Multiple | 7.02 | -1.56 | -0.32 | -1.41 | -4.22 |
| Enterprise Value | 271.24M | 118.47M | 86.34M | 313.29M | 1.40B |
| EV to EBITDA | 7.02 | -1.56 | -0.32 | -1.41 | -4.22 |
| EV to Sales | 2.25 | 0.92 | 10.07 | 4.93 | 68.75 |
| EV to Free Cash Flow | -5.32 | -1.72 | -0.44 | -1.14 | -6.05 |
| EV to Operating Cash Flow | -5.32 | -1.72 | -0.45 | -1.16 | -6.34 |
| Tangible Book Value Per Share | -3.07 | -12.99 | -23.42 | 31.04 | 74.63 |
| Shareholders’ Equity Per Share | -3.07 | -12.99 | -23.42 | 31.04 | 74.63 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | -0.00 | -0.00 | -0.00 |
| Revenue Per Share | 9.63 | 17.22 | 2.02 | 15.58 | 5.43 |
| Net Income Per Share | 2.61 | -11.41 | -65.18 | -55.96 | -90.78 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.90 | 1.06 | 1.02 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.31 | 1.17 | 26.22 | 4.29 | 13.86 |
| SG&A to Revenue | 0.22 | 0.31 | 5.94 | 1.13 | 3.87 |
| Stock-Based Compensation to Revenue | 0.08 | 0.21 | 5.29 | 0.85 | 2.65 |
| Income Quality | -1.56 | 0.80 | 0.70 | 1.18 | 0.65 |
Currency in USD
